LEADER 04180 am 2200769 n 450 001 9910353336103321 005 20150603 010 $a2-919448-24-2 024 7 $a10.4000/books.esb.698 035 $a(CKB)4100000009914050 035 $a(FrMaCLE)OB-esb-698 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/40414 035 $a(PPN)241290287 035 $a(EXLCZ)994100000009914050 100 $a20150617j|||||||| ||| 0 101 0 $apor 135 $auu||||||m|||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDe Afonso X a Afonso XI $eEdição e estudo do texto castelhano dos reinados finais da 2ª redacção da Crónica de 1344 /$fMaria do Rosário Ferreira 210 $aParis $ce-Spania Books$d2015 330 $aA Crónica de 1344, da autoria de Pedro de Barcelos, filho natural do rei D. Dinis de Portugal, é uma das mais emblemáticas obras da cultura ibérica do século XIV, com larga fortuna em Portugal e em Castela ao longo dos séculos seguintes. Teve, porém, uma transmissão textual atribulada ? passando por uma reformulação por volta de 1400, seguida de uma abreviação e continuação pouco antes de 1460, além de sucessivas traduções para castelhano ? da qual resultou uma tradição manuscrita bilingue e lacunar onde não se conta nenhum testemunho português da crónica original. Estas circunstâncias tiveram consequências na difusão editorial do texto. Apesar de a obra ter sido objecto de duas edições críticas, a sua secção final, contemplando os reinados castelhanos de Afonso X a Afonso XI, permanece inédita. De facto, Lindley Cintra publicou, entre 1954 e 1990, o texto português da reformulação c. 1400, que termina em Fernando III; quanto a Diego Catalán, deu à estampa, em 1970, a secção inicial da crónica original, radicalmente alterada pela reformulação e que subsiste apenas em tradução castelhana. Desta forma, a secção da Crónica de 1344 posterior à morte de Fernando III, cujo texto integral se conserva também apenas em castelhano, continua confinada aos manuscritos. O presente trabalho vai dar a conhecer esse relato de um passado recente, que documenta uma visão privilegiada das relações entre os reinos peninsulares nesse conturbado período da história ibérica e constitui uma peça chave no complexo entrecruzamento de textos historiográficos medievais em galego-português e em castelhano. Investigação conduzida no quadro do projecto ?Pedro de Barcelos e a monarquia castelhano-leonesa: estudo e edição da secção final inédita da Crónica de 1344? (XPL/CPC-ELT/1300/2013), financiado pela FCT e pelo COMPET. 606 $aArts & Humanities 606 $aLiterature, Romance 606 $amonarquia castelhana 606 $aAfonso X 606 $aAfonso XI 606 $aCrónica de 1344 606 $aFernando IV 606 $ahistoriografía 606 $aSalado 606 $aSancho IV 606 $ahistoriographie 606 $aPedro de Barcelos 610 $aCrónica de 1344 610 $ahistoriografía 610 $aSalado 610 $amonarquia castelhana 610 $aSancho IV 610 $aFernando IV 610 $aAfonso XI 610 $aAfonso X 615 4$aArts & Humanities 615 4$aLiterature, Romance 615 4$amonarquia castelhana 615 4$aAfonso X 615 4$aAfonso XI 615 4$aCrónica de 1344 615 4$aFernando IV 615 4$ahistoriografía 615 4$aSalado 615 4$aSancho IV 615 4$ahistoriographie 615 4$aPedro de Barcelos 700 $aFerreira$b Maria do Rosário$01288558 701 $aGomes$b Maria Joana$01288554 701 $aGotérrez$b Ricardo Pichel$01288555 701 $aLaranjinha$b Ana Sofia$01288556 701 $aOliveira$b António Resende de$0678312 701 $aPichel Gotérrez$b Ricardo$01288557 701 $aFerreira$b Maria do Rosário$01288558 801 0$bFR-FrMaCLE 906 $aBOOK 912 $a9910353336103321 996 $aDe Afonso X a Afonso XI$93389659 997 $aUNINA LEADER 01150nam 2200337 450 001 9910714540503321 005 20230705060825.0 035 $a(CKB)3710000000300589 035 $a(NjHacI)993710000000300589 035 $a(EXLCZ)993710000000300589 100 $a20230705d2004 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aSketch of Supreme Court Recognition of Fifth Amendment Protection for Acts of Production /$fCharles Doyle 210 1$aWashington, District of Columbia :$cCongressional Research Service,$d2004. 215 $a1 online resource (6 pages) 225 1 $aCRS report for Congress ;$vRS21701 410 0$aCRS report for Congress ;$vRS21701. 606 $aDisclosure of information 615 0$aDisclosure of information. 676 $a332.15320684 700 $aDoyle$b Charles$0700582 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910714540503321 996 $aSketch of Supreme Court Recognition of Fifth Amendment Protection for Acts of Production$93394817 997 $aUNINA LEADER 03504nam 2201105z- 450 001 9910566458203321 005 20220506 035 $a(CKB)5680000000037799 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/80955 035 $a(oapen)doab80955 035 $a(EXLCZ)995680000000037799 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aBiomarkers for Diagnosis, Complications and Therapy Effects in Civilization Diseases Management 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (208 p.) 311 08$a3-0365-3746-5 311 08$a3-0365-3745-7 330 $aThis Special Issue contributes original research and review articles on the role of new protein, molecular, and genetic markers used for the diagnosis and progression of civilization diseases, as well as biomarkers useful in the monitoring the effects of the implemented treatment. 606 $aMedicine and Nursing$2bicssc 610 $aadipokines 610 $aadiponectin 610 $aantiplatelet therapy 610 $abone turnover markers 610 $abreast cancer 610 $acardiovascular disease 610 $acase control study 610 $aCCL11 610 $aCCL24 610 $aCCL26 610 $aCCR3 610 $aCRC 610 $aCrohn's disease 610 $aCrohn's disease (CD) 610 $aCTX-I 610 $adendritic cells 610 $adiabetes 610 $aextracellular matrix 610 $aextracellular matrix components 610 $aFSHR 610 $ahedgehog-interacting protein 610 $ahyaluronan 610 $ahyaluronan (HA) 610 $aimpaired fasting glucose 610 $aimpaired glucose tolerance 610 $ainflammatory bowel disease 610 $ainflammatory bowel diseases (IBD) 610 $ainnate lymphoid cells 610 $ainterleukin 21 610 $ainterleukin 22 610 $aLet-7e 610 $alymphocytes 610 $amacrophages 610 $amicroRNA 610 $amiR-125a-3p 610 $amiR-126 610 $amiR-223 610 $amortality 610 $anewly diagnosed diabetes 610 $aNGS variants 610 $anormal glucose tolerance 610 $aNTX-I 610 $aobesity 610 $aovarian cancer 610 $aoverweight 610 $apersonalized drug therapy 610 $apersonalized medicine 610 $apharmacogenomics 610 $aPICP 610 $aPINP 610 $aplatelet reactivity 610 $aproteins 610 $aRANKL/OPG 610 $arheumatoid arthritis 610 $arheumatology 610 $asoluble part of syndecan-1 (sCD138) 610 $asulfated glycosaminoglycans (sGAG) 610 $aTNF-? inhibitors 610 $atumor microenvironment 610 $atumorigenesis 610 $aulcerative colitis 610 $aulcerative colitis (UC) 615 7$aMedicine and Nursing 700 $aKomosinska-Vassev$b Katarzyna$4edt$01319548 702 $aOlczyk$b Pawel$4edt 702 $aKomosinska-Vassev$b Katarzyna$4oth 702 $aOlczyk$b Pawel$4oth 906 $aBOOK 912 $a9910566458203321 996 $aBiomarkers for Diagnosis, Complications and Therapy Effects in Civilization Diseases Management$93033952 997 $aUNINA LEADER 04122nam 2201369z- 450 001 9910585938303321 005 20220812 035 $a(CKB)5600000000483099 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/91211 035 $a(oapen)doab91211 035 $a(EXLCZ)995600000000483099 100 $a20202208d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aDesign of Micro- and Nanoparticles: Self-Assembly and Application 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (290 p.) 311 08$a3-0365-4764-9 311 08$a3-0365-4763-0 330 $aObjects of nanotechnology such as micro- and nanoparticles are very interesting due to their unique properties. This reprint will be useful to scientists of diverse backgrounds, i.e., material science, organic and inorganic chemistry, biochemistry, and biology. 517 $aDesign of Micro- and Nanoparticles 606 $aTechnology: general issues$2bicssc 610 $a2D monomolecular-layer nanosheets 610 $a2D nanostructures 610 $aAgNPs 610 $aanti-oxidant 610 $aantiviral agent 610 $aantiviral mechanism 610 $abio-imaging 610 $abiomolecule 610 $abismuth titanates 610 $acalcium carbonate 610 $acalix[4]arene 610 $acatalysis 610 $aceria 610 $acoating 610 $acontrast agent 610 $acoronavirus 610 $aCOVID-19 610 $acrystallinity and purity 610 $aDNA sensor 610 $adoxorubicin determination 610 $aDPPC vesicles 610 $adrug delivery 610 $adrug delivery systems 610 $aelectrochemical impedance spectroscopy 610 $aelectropolymerization 610 $aencapsulation 610 $aexfoliation 610 $afluorescein 610 $ageraniol 610 $aheating rate 610 $aheparin/protamine particles 610 $ahepatocyte 610 $ahydrothermal synthesis 610 $aintravenous injection 610 $alacZ protein 610 $alayered oxides 610 $alithium iron phosphate 610 $amaghemite supraparticles 610 $amorphology 610 $amorphology control 610 $an/a 610 $ananomaterials 610 $ananoparticle 610 $ananoparticles 610 $ananorods 610 $ananosheets 610 $ananozyme 610 $aNHC complex 610 $aoxygen radicals 610 $apatchy particles 610 $aperovskites 610 $apillar[5]arene 610 $apoly(Azure B) 610 $apoly(proflavine) 610 $apolyelectrolyte multilayers 610 $apolymorphism 610 $apolyol synthesis 610 $apolystyrene 610 $aprotein delivery 610 $apurification 610 $arhodium nanoparticles 610 $arole of additives 610 $aSARS-CoV-2 610 $aseeded-growth emulsion polymerization 610 $aself-assembling 610 $aseparation 610 $ashrinkage 610 $asilica 610 $asilver nanoparticles 610 $asolvent-induced self-assembly 610 $asurfactants 610 $aSuzuki-Miyaura coupling 610 $asynthesis 610 $atemplate 610 $aterpenoids 610 $atetrazole 610 $atherapeutic approaches 610 $athiacalix[4]arene 610 $atoxicity 610 $aviral mechanism of entry 610 $aX-ray crystal analysis 610 $aX-ray fluorescence 610 $aXFCT 615 7$aTechnology: general issues 700 $aStoikov$b Ivan$4edt$01309881 702 $aPadnya$b Pavel$4edt 702 $aStoikov$b Ivan$4oth 702 $aPadnya$b Pavel$4oth 906 $aBOOK 912 $a9910585938303321 996 $aDesign of Micro- and Nanoparticles: Self-Assembly and Application$93029696 997 $aUNINA